Grail, Inc. (GRAL)
GRAIL, Inc. (GRAL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Shareholder/Analyst Call Transcript
GRAIL, Inc. (GRAL) Shareholder/Analyst Call Transcript
GRAIL's Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
GRAIL NASDAQ: GRAL said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its largest randomized trial was not met.
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL NASDAQ: GRAL said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company's CFO, at a Bank of America event.
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL partners with Epic to embed its Galleri cancer test into EHRs, expanding access across nearly 450 health systems and streamlining clinical workflows nationwide.
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
GRAIL, Inc. (NASDAQ:GRAL) Receives Consensus Recommendation of “Hold” from Analysts
Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) have received a consensus recommendation of "Hold" from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the
Grail CEO Bob Ragusa to retire, Josh Ofman named successor
Cancer test maker Grail said on Thursday that chief executive Bob Ragusa will retire effective June 1, and the company's president, Josh Ofman, will take over the helm.
'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection
A T206 Honus Wagner baseball card in a family collection for 116 years was sold for $5.124 million at auction, becoming the third-most expensive ever for this specific card.
Biotech Stock Plummets on Cancer Screening Trial Results
Biotech stock Grail Inc (NASDAQ:GRAL) is taking a nosedive today, brushing off better-than-expected fourth-quarter results after the company's three-year cancer screening trial failed to meet its main goal.
